Liquidia Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Liquidia şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-11.2%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-11.2%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Is Liquidia (NASDAQ:LQDA) A Risky Investment?

Jul 18

Broker Revenue Forecasts For Liquidia Corporation (NASDAQ:LQDA) Are Surging Higher

Jan 19

Liquidia Corporation's (NASDAQ:LQDA) P/S Still Appears To Be Reasonable

Dec 20

Is Liquidia (NASDAQ:LQDA) Using Debt In A Risky Way?

Aug 17

Need To Know: Analysts Are Much More Bullish On Liquidia Corporation (NASDAQ:LQDA) Revenues

Mar 18

Is Liquidia (NASDAQ:LQDA) Using Too Much Debt?

Feb 06

Liquidia (NASDAQ:LQDA) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Oct 25

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: LQDA şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: LQDA şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Liquidia Piyasaya Karşı Temettü Getirisi

LQDA temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (LQDA)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (LQDA) (3 yıla kadar)	0%

Önemli Temettü: LQDA şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, LQDA şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: LQDA şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: LQDA herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Liquidia Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Liquidia Corporation to Report Q3, 2024 Results on Nov 13, 2024

Liquidia Corporation to Report Q3, 2024 Results on Nov 11, 2024

Liquidia Corporation Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting

Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million.

Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million.

Liquidia Corporation Files Litigation to Challenge Regulatory Exclusivity Blocking Access to Yutrepia (Treprostinil) Inhalation Powder for Patients Suffering with PAH and PH-ILD

Consensus revenue estimates decrease by 49%, EPS upgraded

No longer forecast to breakeven

New minor risk - Share price stability

Price target decreased by 7.1% to US$25.71

Liquidia Corporation Announces U.S. Food and Drug Administration Grants Tentative Approval of YUTPIA®? (Treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Consensus revenue estimates fall by 45%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

Liquidia Corporation to Report Q2, 2024 Results on Aug 07, 2024

Is Liquidia (NASDAQ:LQDA) A Risky Investment?

Price target increased by 10% to US$27.67

No longer forecast to breakeven

District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch

Consensus revenue estimates increase by 18%, EPS downgraded

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

No longer forecast to breakeven

Liquidia Corporation to Report Q1, 2024 Results on May 14, 2024

Liquidia Corporation, Annual General Meeting, Jun 20, 2024

Liquidia Corporation Provides Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA Approval of YUTREPIA™ (treprostinil) Inhalation Powder

CEO & Director recently sold US$452k worth of stock

Consensus EPS estimates fall by 15%, revenue upgraded

Price target increased by 29% to US$27.33

Full year 2023 earnings: EPS and revenues miss analyst expectations

Liquidia Corporation to Report Fiscal Year 2023 Results on Mar 13, 2024

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA (Treprostinil) Inhalation Powder

Liquidia Corporation Announces the Launch of Yutrepiatm (Treprostinil) Inhalation Powder

Broker Revenue Forecasts For Liquidia Corporation (NASDAQ:LQDA) Are Surging Higher

Liquidia Corporation Announces Updates to Operations Leadership

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

Liquidia Corporation Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

Liquidia Corporation announced that it expects to receive $74.999999 million in funding from Legend Aggregator, LP

Insufficient new directors

Forecast to breakeven in 2026

Price target increased by 31% to US$18.29

Independent Director recently bought US$2.0m worth of stock

Liquidia Corporation's (NASDAQ:LQDA) P/S Still Appears To Be Reasonable

Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $24.999999 million.

New minor risk - Shareholder dilution

Liquidia Corporation has filed a Follow-on Equity Offering in the amount of $24.999999 million.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Liquidia Corporation to Report Q3, 2023 Results on Nov 07, 2023

FDA Accepts Liquidia Corporation's Submission to Add PH-ILD to YUTREPIA™ Label

United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office

Is Liquidia (NASDAQ:LQDA) Using Debt In A Risky Way?

Consensus EPS estimates fall by 34%, revenue upgraded

New minor risk - Profitability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Liquidia Corporation to Report Q2, 2023 Results on Aug 10, 2023

Liquidia Corporation Submits Amendment to Add Ph-Ild Indication to Tentatively Approved Nda for Yutpia (Treprostinil) Inhalation Powder

Liquidia Corporation Announces U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation

Price target increased by 15% to US$16.17

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.30 loss in 1Q 2022)

Need To Know: Analysts Are Much More Bullish On Liquidia Corporation (NASDAQ:LQDA) Revenues

No longer forecast to breakeven

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Is Liquidia (NASDAQ:LQDA) Using Too Much Debt?

Forecast to breakeven in 2025

Price target increased to US$14.83

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Liquidia Corporation to Report Q3, 2022 Results on Nov 08, 2022

Liquidia (NASDAQ:LQDA) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme